Portable device zaps brain tumors in new melanoma trial
NCT ID NCT04129515
Summary
This study aimed to test the safety and effectiveness of a portable electrical device (NovoTTF-200A) when used together with the immunotherapy drug pembrolizumab for people with melanoma that had spread to the brain. The device, worn like a backpack, delivers low-intensity electrical fields intended to stop cancer cell growth and potentially make the tumor more responsive to the drug. The trial was designed for adults with newly diagnosed brain metastases who had not yet received surgery or radiation for those specific tumors.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for METASTATIC MELANOMA are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Lifespan Cancer Institute
Providence, Rhode Island, 02903, United States
Conditions
Explore the condition pages connected to this study.